Publications by authors named "Helen Gall"

Claim this Profile
M
Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab.
Saskia Jam Santegoets, Anita Gm Stam, Sinéad M Lougheed, Helen Gall, Karin Jooss

J Immunother Cancer· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch.
Christine B Boers-Doets, Hans Gelderblom, Mario E Lacouture, Jason M Bredle, Joel B Epstein, Helen Gall

Eur J Oncol Nurs· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.
Saskia J A M Santegoets, Anita G M Stam, Sinéad M Lougheed, Helen Gall, Petra E T Scholten

Cancer Immunol Immunother· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Alfons J M van den Eertwegh, Jurjen Versluis, H Pieter van den Berg, Saskia J A M Santegoets, R Jeroen A van Moorselaar, Helen E Gall

Lancet Oncol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183.
Linda E Bröker, Stephan A Veltkamp, Elisabeth I Heath, Bart C Kuenen, Helen Gall

Clin Cancer Res· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer.
Herlinde Dumez, Helen Gall, Renaud Capdeville, Catherine Dutreix, Allan T van Oosterom

Anticancer Drugs· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity.
Linda E Bröker, Filip Y F L de Vos, Cees J van Groeningen, Bart C Kuenen, Helen E Gall

Clin Cancer Res· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study.
Johanna M G H van Riel, Cees J van Groeningen, Mark A Kedde, Helen Gall, Johanna M A Leisink

Clin Cancer Res· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis